JP2016526558A5 - - Google Patents

Download PDF

Info

Publication number
JP2016526558A5
JP2016526558A5 JP2016524294A JP2016524294A JP2016526558A5 JP 2016526558 A5 JP2016526558 A5 JP 2016526558A5 JP 2016524294 A JP2016524294 A JP 2016524294A JP 2016524294 A JP2016524294 A JP 2016524294A JP 2016526558 A5 JP2016526558 A5 JP 2016526558A5
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
alkyl
cycloalkyl
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016524294A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016526558A (ja
JP6458018B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/044922 external-priority patent/WO2015002894A1/en
Publication of JP2016526558A publication Critical patent/JP2016526558A/ja
Publication of JP2016526558A5 publication Critical patent/JP2016526558A5/ja
Application granted granted Critical
Publication of JP6458018B2 publication Critical patent/JP6458018B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016524294A 2013-07-02 2014-06-30 キナーゼ阻害剤としてのプリノン化合物 Expired - Fee Related JP6458018B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361842321P 2013-07-02 2013-07-02
US61/842,321 2013-07-02
PCT/US2014/044922 WO2015002894A1 (en) 2013-07-02 2014-06-30 Purinone compounds as kinase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018237711A Division JP2019069977A (ja) 2013-07-02 2018-12-19 キナーゼ阻害剤としてのプリノン化合物

Publications (3)

Publication Number Publication Date
JP2016526558A JP2016526558A (ja) 2016-09-05
JP2016526558A5 true JP2016526558A5 (esLanguage) 2017-07-06
JP6458018B2 JP6458018B2 (ja) 2019-01-23

Family

ID=52144143

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016524294A Expired - Fee Related JP6458018B2 (ja) 2013-07-02 2014-06-30 キナーゼ阻害剤としてのプリノン化合物
JP2018237711A Pending JP2019069977A (ja) 2013-07-02 2018-12-19 キナーゼ阻害剤としてのプリノン化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018237711A Pending JP2019069977A (ja) 2013-07-02 2018-12-19 キナーゼ阻害剤としてのプリノン化合物

Country Status (5)

Country Link
US (3) US9637487B2 (esLanguage)
EP (1) EP3016953A4 (esLanguage)
JP (2) JP6458018B2 (esLanguage)
CA (1) CA2917167A1 (esLanguage)
WO (1) WO2015002894A1 (esLanguage)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9416132B2 (en) 2011-07-21 2016-08-16 Tolero Pharmaceuticals, Inc. Substituted imidazo[1,2-b]pyridazines as protein kinase inhibitors
US8501724B1 (en) * 2012-01-31 2013-08-06 Pharmacyclics, Inc. Purinone compounds as kinase inhibitors
CA2905993C (en) 2013-03-14 2022-12-06 Tolero Pharmaceuticals, Inc. Substituted 4-amino-pyrimidinyl-2-amino-phenyl derivatives and pharmaceutical compositions thereof for use as jak2 and alk2 inhibitors
US9637487B2 (en) * 2013-07-02 2017-05-02 Pharmacyclics Llc Purinone compounds as kinase inhibitors
WO2015151006A1 (en) 2014-03-29 2015-10-08 Lupin Limited Substituted purine compounds as btk inhibitors
WO2015170266A1 (en) 2014-05-07 2015-11-12 Lupin Limited Substituted pyrimidine compounds as btk inhibitors
CN105753863B (zh) * 2015-09-11 2018-07-31 东莞市真兴贝特医药技术有限公司 氧代二氢咪唑并吡啶类化合物及其应用
CN106146518A (zh) * 2016-06-30 2016-11-23 苏州爱玛特生物科技有限公司 一种布鲁顿酪氨酸激酶抑制剂中间体及其制备方法
WO2018002958A1 (en) 2016-06-30 2018-01-04 Sun Pharma Advanced Research Company Limited Novel hydrazide containing compounds as btk inhibitors
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
AR110998A1 (es) 2017-02-24 2019-05-22 Gilead Sciences Inc Inhibidores de la tirosina cinasa de bruton
JP2020508326A (ja) 2017-02-24 2020-03-19 ギリアド サイエンシズ, インコーポレイテッド ブルトン型チロシンキナーゼの阻害剤
EP3691687A1 (en) * 2017-10-04 2020-08-12 Celgene Corporation Compositions and methods of use of cis-4-[2-{[(3s,4r)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9h-purin-9-yl]-1-methylcyclohexane-1-carboxamide
JP7050165B2 (ja) 2018-02-26 2022-04-07 ギリアード サイエンシーズ, インコーポレイテッド Hbv複製阻害剤としての置換ピロリジン化合物
CA3096984A1 (en) 2018-04-05 2019-10-10 Sumitomo Dainippon Pharma Oncology, Inc. Axl kinase inhibitors and use of the same
CN117959303A (zh) 2018-04-13 2024-05-03 住友制药肿瘤公司 用于治疗骨髓增殖性肿瘤和与癌症相关的纤维化的pim激酶抑制剂
JP2021530554A (ja) 2018-07-26 2021-11-11 スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド 異常なacvr1発現を伴う疾患を処置するための方法およびそこで使用するためのacvr1阻害剤
CA3224985C (en) 2018-07-31 2025-11-18 Loxo Oncology, Inc. SPRAY-DRIED DISPERSIONS, FORMULATIONS AND POLYMORPHIES OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)(1,1,1-TRIFLUOROPROPANE-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE
EP3924351B1 (en) 2019-02-12 2025-05-21 Sumitomo Pharma America, Inc. Crystalline form of the hydrochloride salt of 2-((1r,4r)-4-((3-(3-(trifluoromethyl)phenyl) imidazo[1,2-b]pyridazin-6-yl)amino)cyclohexyl)propan-2-ol
EP3942045A1 (en) 2019-03-21 2022-01-26 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
WO2021038540A1 (en) 2019-08-31 2021-03-04 Sun Pharma Advanced Research Company Limited Cycloalkylidene carboxylic acids and derivatives as btk inhibitors
JP2023500906A (ja) 2019-11-08 2023-01-11 インサーム(インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル) キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
KR102409595B1 (ko) * 2020-06-29 2022-06-17 한국과학기술연구원 단백질 카이네이즈 csf-1r 억제제로서의 신규 퓨리논 유도체
CN114573586B (zh) * 2020-11-28 2023-11-03 杭州和正医药有限公司 一种抑制布鲁顿酪氨酸激酶活性的多环化合物、药物组合物及其应用
WO2022140246A1 (en) 2020-12-21 2022-06-30 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
EP4611753A1 (en) 2022-10-31 2025-09-10 Sumitomo Pharma America, Inc. Pim1 inhibitor for treating myeloproliferative neoplasms

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100540046B1 (ko) 1997-11-12 2006-01-10 미쓰비시 가가꾸 가부시키가이샤 퓨린유도체 및 이를 유효성분으로 함유하는 의약
JP3957023B2 (ja) * 1997-11-12 2007-08-08 三菱化学株式会社 プリン誘導体及びそれを有効成分として含む医薬
JP2003509427A (ja) * 1999-09-17 2003-03-11 アボツト・ゲー・エム・ベー・ハー・ウント・コンパニー・カーゲー 治療剤としてのキナーゼ阻害剤
US7071199B1 (en) * 1999-09-17 2006-07-04 Abbott Gmbh & Cco. Kg Kinase inhibitors as therapeutic agents
US7244744B2 (en) * 2001-11-01 2007-07-17 Icagen, Inc. Piperidines
US20090023723A1 (en) * 2005-09-21 2009-01-22 Pharmacopeia Drug Discovery, Inc. Purinone derivatives for treating neurodegenerative diseases
EP2526934B1 (en) * 2006-09-22 2015-12-09 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
US20080119496A1 (en) * 2006-11-16 2008-05-22 Pharmacopeia Drug Discovery, Inc. 7-Substituted Purine Derivatives for Immunosuppression
US20120101113A1 (en) 2007-03-28 2012-04-26 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
EP2954900A1 (en) 2007-03-28 2015-12-16 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
TWI500617B (zh) 2010-05-31 2015-09-21 Ono Pharmaceutical Co Purine ketone derivatives
US8703767B2 (en) * 2011-04-01 2014-04-22 University Of Utah Research Foundation Substituted N-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase BTK inhibitors
US8377946B1 (en) * 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
US8501724B1 (en) * 2012-01-31 2013-08-06 Pharmacyclics, Inc. Purinone compounds as kinase inhibitors
US9637487B2 (en) * 2013-07-02 2017-05-02 Pharmacyclics Llc Purinone compounds as kinase inhibitors
PE20160560A1 (es) 2013-09-30 2016-06-09 Pharmacyclics Llc DERIVADOS DE PIRAZOLO[3,4-d]PIRIMIDIN COMO INHIBIDORES IRREVERSIBLES DE LA TIROSINA CINASA DE BRUTON (BTK)

Similar Documents

Publication Publication Date Title
JP2016526558A5 (esLanguage)
JP2018513150A5 (esLanguage)
RU2477723C2 (ru) Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
JP2019524883A5 (esLanguage)
RU2020110780A (ru) Ингибитор fgfr и его медицинское применение
JP2018529650A5 (esLanguage)
JP2015509927A5 (esLanguage)
JP2020531422A5 (esLanguage)
JP2019527718A5 (esLanguage)
JP2018519357A5 (esLanguage)
JP2015520140A5 (esLanguage)
JP2016515561A5 (esLanguage)
JP2019500387A5 (esLanguage)
JP2018115201A5 (esLanguage)
JP2017523225A5 (esLanguage)
JP2014511891A5 (esLanguage)
JP2017535614A5 (esLanguage)
JP2013519645A5 (esLanguage)
JP2015505296A5 (esLanguage)
JP2017523143A5 (esLanguage)
JP2016505614A5 (esLanguage)
JP2012505916A5 (esLanguage)
JP2013510120A5 (esLanguage)
JP2014015465A5 (esLanguage)
JP2017504635A5 (esLanguage)